Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA issues guidance for antibacterial trials

FDA on Friday warned sponsors of antibacterial compounds that prior SPA commitments for protocols involving non-inferiority

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE